Fracture Prevention with Zoledronate in Older Women with Osteopenia.

@article{Reid2018FracturePW,
  title={Fracture Prevention with Zoledronate in Older Women with Osteopenia.},
  author={Ian R Reid and Anne M. Horne and Borislav Mihov and Angela Stewart and E. Carlton Garratt and Sumwai Wong and Katy R. Wiessing and Mark J Bolland and Sonja T Bastin and Gregory David Gamble},
  journal={The New England journal of medicine},
  year={2018},
  volume={379 25},
  pages={
          2407-2416
        }
}
BACKGROUND Bisphosphonates prevent fractures in patients with osteoporosis, but their efficacy in women with osteopenia is unknown. Most fractures in postmenopausal women occur in those with osteopenia, so therapies that are effective in women with osteopenia are needed. METHODS We conducted a 6-year, double-blind trial involving 2000 women with osteopenia (defined by a T score of -1.0 to -2.5 at either the total hip or the femoral neck on either side) who were 65 years of age or older… CONTINUE READING

References

Publications referenced by this paper.
SHOWING 1-10 OF 28 REFERENCES

Association of Alendronate and Risk of Cardiovascular Events in Patients With Hip Fracture.

Chor-Wing Sing, Angel Y. S. Wong, +7 authors Ching-Lung Cheung
  • Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research
  • 2018

Effects of estrogen plus progestin on risk of fracture and bone mineral density: the The New England Journal of Medicine Downloaded from nejm.org by JULES

JA Cauley, J Robbins, Z Chen
  • LEVIN on December
  • 2018

Clinician’s Guide to Prevention and Treatment of Osteoporosis

F. Cosman, S. J. Beur, +4 authors R. Lindsay
  • Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
  • 2014

Similar Papers

Loading similar papers…